Cost-effectiveness and cost utility analysis of three pneumococcal conjugate vaccines in children of Peru

BMC Public Health

Oleksandr Topachevskyi⁴  Maria Mercedes Castrejon Alba³  Aldo Amador Navarro Rojas²  Juan Carlos Tirado⁵  Jorge Alberto Gomez¹ 

[1] Carlos Casares, 3690 – B1644CD, Victoria, Buenos Aires, Argentina;GSK Peru, Lima, Peru;GSK Panama, Panama City, Panama;GSK Belgium, Wavre, Belgium;Complejo Hospitalario San Pablo, Lima, Peru

关键词: Peru;    Non-typeable Haemophilus influenzae;    Acute otitis media;    Cost-effectiveness;    Pneumococcal vaccines;    Pneumococcal disease;   

Others  :  1161600
DOI  :  10.1186/1471-2458-13-1025

 received in 2012-07-19, accepted in 2013-10-25,  发布年份 2013

【 摘 要 】

Background

The clinical and economic burden associated with invasive and non-invasive pneumococcal and non-typeable Haemophilus influenzae (NTHi) diseases is substantial in the Latin America and Caribbean region, where pneumococcal vaccines have only been introduced to a few countries. This study analyzed the cost-effectiveness and cost utility of three different pneumococcal conjugate vaccines (PCVs) for Peru.

Methods

A Markov model that simulated the disease processes in a birth cohort over a lifetime, within 1,128 month cycles was used to evaluate the cost-effectiveness of 10-valent pneumococcal NTHi protein D conjugate vaccine (PHiD-CV) and 7- and 13-valent PCVs (PCV-7 and PCV-13). Expected quality-adjusted life years (QALYs), cost-savings and incremental cost-effectiveness ratios (ICERs) were calculated.

Results

Without vaccination, pneumonia was associated with the greatest health economic burden (90% of QALYs lost and 63% of lifetime direct medical costs); while acute otitis media (AOM) was responsible for 1% of QALYs lost and 25% of direct medical costs. All vaccines were predicted to be cost-effective for Peru, with PHiD-CV being most cost-effective. PHiD-CV was predicted to generate 50 more QALYs gained and required a reduced investment (−US$ 3.4 million) versus PCV-13 (discounted data), and was therefore dominant and cost saving. The probabilistic sensitivity analysis showed that PHiD-CV generated more QALYs gained at a reduced cost than PCV-13 in 84% of the simulations and less QALYs gains at a reduced cost in 16%. Additional scenarios using different assumptions on vaccine efficacies based on previous evidence were explored, but no significant change in the overall cost-effective results were observed.

Conclusions

The results of this modeling study predict that PCVs are likely to be a cost-effective strategy to help relieve the epidemiological and economic burden associated with pediatric pneumococcal and NTHi diseases for Peru. PHiD-CV is likely to be a dominant (better health gains at a reduced net cost) intervention compared to PCV-13 or PCV-7. The most significant drivers for these results are the better health and economic profile of PHiD-CV against AOM and its reduced cost per dose available through the PAHO Revolving Fund in the LAC region.

【 授权许可】

   
2013 Gomez et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

【 参考文献 】

• [1]O’Brien KL, Wolfson LJ, Watt JP, Henkle E, Deloria-Knoll M, McCall N, Lee E, Mulholland K, Levine OS, Cherian T, Hib and Pneumococcal Global Burden of Disease Study Team: Burden of disease caused by Streptococcus pneumoniae in children younger than 5 years: global estimates. Lancet 2009, 374(9693):893-902.
• [2]Valenzuela MT, O’Loughlin R, De La Hoz F, Gomez E, Constenla D, Sinha A, Valencia JE, Flannery B, De Quadros CA: The burden of pneumococcal disease among Latin American and Caribbean children: review of the evidence. Rev Panam Salud Publica 2009, 25(3):270-279.
• [3]Ministerio de Salud: Resolución Ministerial No 457–2009[ftp://ftp2.minsa.gob.pe/normaslegales/2009/RM457-2009.pdf]
• [4]Ministerio de Salud: Convenio de cooperación técnica entre la Organización Panamericana de la Salud (OPS) y el Ministerio de Salud de la República del Peru (MINSA) para la adquisición de vacunas, jeringas y otros insumos relacionados. [ftp://ftp2.minsa.gob.pe/descargas/Transparencia/01InformacionInst/archivolegaldigital/Convenio2012/Conv002-2012-MINSA.pdf]
• [5]World Health Organization: WHO Vaccine Preventable Diseases Monitoring System. 2011 Global summary. [http://apps.who.int/immunization_monitoring/globalsummary/countries?countrycriteria[country][]=PER&commit=OK webcite]
• [6]Talbird SE, Taylor TN, Caporale J, Ismaila AS, Gomez J: Residual economic burden of Streptococcus pneumoniae- and nontypeable Haemophilus influenzae-associated disease following vaccination with PCV-7: a multicountry analysis. Vaccine 2010, 28(Suppl 6):G14-G22.
• [7]Prymula R, Schuerman L: 10-valent pneumococcal nontypeable Haemophilus influenzae PD conjugate vaccine: synflorix. Expert Rev Vaccines 2009, 8(11):1479-1500.
• [8]Duggan ST: Pneumococcal polysaccharide conjugate vaccine (13-valent, adsorbed) [prevenar 13®]. Drugs 2010, 70(15):1973-1986.
• [9]Bolaños Díaz R, Mezones-Holguín E, Fiestas Solórzano V, Suárez Moreno V, Sanabria C: Evaluación económica de las vacunas hepta-, deca- y trece-valente para la prevención de neumonía asociada al Streptococcus pneumoniae en niños menores de 5 años en el Perú. [http://www.ins.gob.pe/repositorioaps/0/4/jer/evidencias/Nota%20t%C3%A9cnica-6_Eval%20econ%20de%20las%20vacunas%20hepta-,%20deca-%20y%20trece-valente.pdf webcite]
• [10]Standaert B, Demarteau N, Talbird S, Mauskopf J: Modelling the effect of conjugate vaccines in pneumococcal disease: cohort or population models? Vaccine 2010, 28(Suppl 6):G30-G38.
• [11]Knerer G, Ismaila A, Pearce D: Health and economic impact of PHiD-CV in Canada and the UK: a Markov modelling exercise. J Med Econ 2012, 15(1):61-76.
• [12]Instituto Nacional de Estadística e Informática: Cuadro nº 1: Población total, por área urbana y rural, y sexo, según departamento, provincia, distrito y edades simples. [http://desa.inei.gob.pe/censos2007/tabulados/ webcite]
• [13]Prymula R, Peeters P, Chrobok V, Kriz P, Novakova E, Kaliskova E, Kohl I, Lommel P, Poolman J, Prieels JP, Schuerman L: Pneumococcal capsular polysaccharides conjugated to protein D for prevention of acute otitis media caused by both Streptococcus pneumoniae and non-typable Haemophilus influenzae: a randomised double-blind efficacy study. Lancet 2006, 367(9512):740-748.
• [14]García Martí S, Colantonio L, Bardach A, Galante J, Lopez A, Caporale J, Knerer G, Gomez JA, Augustovski F, Pichon Riviere A: A cost-effectiveness analysis of a 10-valent pneumococcal conjugate vaccine in children in six Latin American countries. Cost Effectiveness and Resource Allocation 2013, 11:21. doi:10.1186/1478-7547-11-21 BioMed Central Full Text
• [15]Linstone HA, Turoff M: The Delphi Method: Techniques and Applications. Addison-Wesley; 2002.
• [16]Cintra O, Iwamoto M, Iwamoto M, Delcaro L, Domingos J, Paula F, Ferraz I, Matsuno A, Arruda E: Incidence of acute otitis media (AOM) and community acquired pneumonia (CAP) in a Brazilian community level primary care services (PCS) [abstract]. Pediatr Infect Dis J 2009, 28(6):165.
• [17]Gutiérrez Trujillo G, Martínez González MC, Guiscafré Gallardo H, Gómez GP, Munoz O: Patrones de prescripción de antimicrobianos en infecciones respiratorias agudas: encuesta en la población rural / Patterns of antimicrobial-drug prescriptions in acute respiratory infections: survey performed in the Mexican rurar area. Rev Fac Med UNAM 1989, 32(4):134-136.
• [18]Lopez I, Sepulveda H, Valdez I: Frecuencia de otitis media aguda en menores de 5 anos bajo control. Revista Pediatria (Santiago) 1998, 41:21-25.
• [19]Leibovitz E, Jacobs MR, Dagan R: Haemophilus influenzae: a significant pathogen in acute otitis media. Pediatr Infect Dis J 2004, 23(12):1142-1152.
• [20]Gabastou JM, Agudelo CI, Brandileone MC, Castaneda E, de Lemos AP, Di Fabio JL, Grupo de Laboratorio de SIREVA II: [Characterization of invasive isolates of S. pneumoniae, H. influenzae, and N. meningitidis in Latin America and the Caribbean: SIREVA II, 2000–2005]. Rev Panam Salud Publica 2008, 24(1):1-15.
• [21]de la Salud OP: Informe Regional de SIREVA II, 2006. Datos por país y por grupos de edad sobre las características de los aislamientos de Streptococcus pneumoniae, Haemophilus influenzae y Neisseria meningitidis en procesos invasores. [http://www.paho.org/Spanish/AD/THS/EV/labs_Sireva_II_2006.pdf webcite]
• [22]Organización Panamerica de la Salud: Informe Regional de SIREVA II: datos por país y por grupos de edad sobre las características de los aislamientos de Streptococcus pneumoniae, Haemophilus influenzae y Neisseria meningitidis en procesos invasores, 2000–2005. [http://www.paho.org/Spanish/AD/THS/EV/LABS-Sireva.pdf webcite]
• [23]Bernstein SJ, Hofer TP, Meijler AP, Rigter H: Setting standards for effectiveness: a comparison of expert panels and decision analysis. Int J Qual Health Care 1997, 9(4):255-263.
• [24]Whitney CG, Pilishvili T, Farley MM, Schaffner W, Craig AS, Lynfield R, Nyquist AC, Gershman KA, Vazquez M, Bennett NM, Reingold A, Thomas A, Glode MP, Zell ER, Jorgensen JH, Beall B, Schuchat A: Effectiveness of seven-valent pneumococcal conjugate vaccine against invasive pneumococcal disease: a matched case–control study. Lancet 2006, 368(9546):1495-1502.
• [25]Black SB, Shinefield HR, Ling S, Hansen J, Fireman B, Spring D, Noyes J, Lewis E, Ray P, Lee J, Hackell J: Effectiveness of heptavalent pneumococcal conjugate vaccine in children younger than five years of age for prevention of pneumonia. Pediatr Infect Dis J 2002, 21(9):810-815.
• [26]Hansen J, Black S, Shinefield H, Cherian T, Benson J, Fireman B, Lewis E, Ray P, Lee J: Effectiveness of heptavalent pneumococcal conjugate vaccine in children younger than 5 years of age for prevention of pneumonia: updated analysis using World health organization standardized interpretation of chest radiographs. Pediatr Infect Dis J 2006, 25(9):779-781.
• [27]Klugman KP, Madhi SA, Huebner RE, Kohberger R, Mbelle N, Pierce N, Vaccine Trialists Group: A trial of a 9-valent pneumococcal conjugate vaccine in children with and those without HIV infection. N Engl J Med 2003, 349(14):1341-1348.
• [28]Cutts FT, Zaman SM, Enwere G, Jaffar S, Levine OS, Okoko JB, Oluwalana C, Vaughan A, Obaro SK, Leach A, McAdam KP, Biney E, Saaka M, Onwuchekwa U, Yallop F, Pierce NF, Greenwood BM, Adegbola RA, Gambian Pneumococcal Vaccine Trial Group: Efficacy of nine-valent pneumococcal conjugate vaccine against pneumonia and invasive pneumococcal disease in The Gambia: randomised, double-blind, placebo-controlled trial. Lancet 2005, 365(9465):1139-1146.
• [29]Madhi SA, Kuwanda L, Cutland C, Klugman KP: The impact of a 9-valent pneumococcal conjugate vaccine on the public health burden of pneumonia in HIV-infected and -uninfected children. Clin Infect Dis 2005, 40(10):1511-1518.
• [30]Lucero MG, Nohynek H, Williams G, Tallo V, Simoes EA, Lupisan S, Sanvictores D, Forsyth S, Puumalainen T, Ugpo J, Lechago M, de Campo M, Abucejo-Ladesma E, Sombrero L, Nissinen A, Soininen A, Ruutu P, Riley I, Makela HP: Efficacy of an 11-valent pneumococcal conjugate vaccine against radiologically confirmed pneumonia among children less than 2 years of age in the Philippines: a randomized, double-blind, placebo-controlled trial. Pediatr Infect Dis J 2009, 28(6):455-462.
• [31]Lucero MG, Dulalia VE, Nillos LT, Williams G, Parreno RA, Nohynek H, Riley ID, Makela H: Pneumococcal conjugate vaccines for preventing vaccine-type invasive pneumococcal disease and X-ray defined pneumonia in children less than two years of age. Cochrane Database Syst Rev 2009., 4CD004977
• [32]Eskola J, Kilpi T, Palmu A, Jokinen J, Haapakoski J, Herva E, Takala A, Kayhty H, Karma P, Kohberger R, Siber G, Makela PH, Finnish Otitis Media Study Group: Efficacy of a pneumococcal conjugate vaccine against acute otitis media. N Engl J Med 2001, 344(6):403-409.
• [33]Sáez-Llorens X, Tregnaghi MW, López P, Abate H, Pósleman A, Cortes-Barbosa C, Carabajal C, Calvo A, Wong D, Falaschi A, Gómes C, Caicedo Y, Leandro A, Avakian J, Esquivel R, Sierra A, Castrejón MM, Lepetic A, Lommel P, Hausdorff WP, Borys D, Ruiz Guiñazú J, Ortega-Barría E, Yarzábal JP, Schuerman L: Design/setting of COMPAS: a Latin American trial evaluating the efficacy of 10-valent pneumococcal non-typable Haemophilus influenza protein-D conjugate vaccine (PHiD-CV). The Hague, The Netherlands: 29th Annual Meeting of the European Society for Pediatric Infectious Diseases (ESPID); 2011.
• [34]Tregnaghi MW, Sáez-Llorens X, López P, Abate H, Smith E, Pósleman A, Calvo A, Wong D, Cortes-Barbosa C, Ceballos A, Tregnaghi M, Sierra A, Márquez V, Rodriguez M, Troitiño M, Rüttimann R, Castrejón MM, Lepetic A, Lommel P, Hausdorff WP, Borys D, Ruiz GJ, Ortega-Barría E, Yarzábal JP, Schuerman L: Evidencia de la eficacia de la vacuna decavalente antineumococcica conjugada a la proteína D del Haemophilus influenzae no tipificable (PHiD-CV por su siglas en inglés) frente a la neumonía adquirida en la comunidad en América Latina : resultados del estudio COMPAS. Punta Cana, Republica Dominicana: XIV Congreso Latinoamericano de Infectología Pediátrica (SLIPE); 2011.
• [35]Tregnaghi MW, Sáez-Llorens X, López P, Abate H, Smith E, Pósleman A, Calvo A, Wong D, Cortes-Barbosa C, Ceballos A, Tregnaghi M, Sierra A, Márquez V, Rodriguez M, Troitiño M, Rüttimann R, Castrejón MM, Lepetic A, Lommel P, Hausdorff WP, Borys D, Ruiz Guiñazú J, Ortega-Barría E, Yarzábal JP, Schuerman L: Evaluating the efficacy of 10-valent pneumococcal non-typable Haemophilus influenzae protein-D conjugate vaccine (PHiD-CV) against community-adquired pneumonia in Latin America. The Hague, The Netherlands: 29th Annual Meeting of the European Society for Pediatric Infectious Diseases (ESPID); 2011.
• [36]Vesikari T, Wysocki J, Chevallier B, Karvonen A, Czajka H, Arsene JP, Lommel P, Dieussaert I, Schuerman L: Immunogenicity of the 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) compared to the licensed 7vCRM vaccine. Pediatr Infect Dis J 2009, 28(4 Suppl):S66-S76.
• [37]Bermal N, Szenborn L, Chrobot A, Alberto E, Lommel P, Gatchalian S, Dieussaert I, Schuerman L: The 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) coadministered with DTPw-HBV/Hib and poliovirus vaccines: assessment of immunogenicity. Pediatr Infect Dis J 2009, 28(4 Suppl):S89-S96.
• [38]Park IH, Moore MR, Treanor JJ, Pelton SI, Pilishvili T, Beall B, Shelly MA, Mahon BE, Nahm MH, Active Bacterial Core Surveillance Team: Differential effects of pneumococcal vaccines against serotypes 6A and 6C. J Infect Dis 2008, 198(12):1818-1822.
• [39]Hausdorff WP, Hoet B, Schuerman L: Do pneumococcal conjugate vaccines provide any cross-protection against serotype 19A? BMC Pediatr 2010, 10:4. BioMed Central Full Text
• [40]European Medicines Agency (EMEA) Committee For Medicinal Products For Human Use (CHMP): Guideline on clinical evaluation of new vaccines. [http://www.emea.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/09/WC500003870.pdf webcite]
• [41]Bardach A, Ciapponi A, Garcia-Marti S, Glujovsky D, Mazzoni A, Fayad A, Colindres RE, Gentile A: Epidemiology of acute otitis media in children of Latin America and the Caribbean: a systematic review and meta-analysis. Int J Pediatr Otorhinolaryngol 2011, 75(9):1062-1070.
• [42]Constenla DO: Economic impact of pneumococcal conjugate vaccination in Brazil, Chile, and Uruguay. Rev Panam Salud Publica 2008, 24(2):101-112.
• [43]Bennett JE, Sumner W 2nd, Downs SM, Jaffe DM: Parents’ utilities for outcomes of occult bacteremia. Arch Pediatr Adolesc Med 2000, 154(1):43-48.
• [44]Oh PI, Maerov P, Pritchard D, Knowles SR, Einarson TR, Shear NH: A cost-utility analysis of second-line antibiotics in the treatment of acute otitis media in children. Clin Ther 1996, 18(1):160-182.
• [45]Oostenbrink R, Oostenbrink JB, Moons KG, Derksen-Lubsen G, Essink-Bot ML, Grobbee DE, Redekop WK, Moll HA: Cost-utility analysis of patient care in children with meningeal signs. Int J Technol Assess Health Care 2002, 18(3):485-496.
• [46]Morrow A, De Wals P, Petit G, Guay M, Erickson LJ: The burden of pneumococcal disease in the Canadian population before routine use of the seven-valent pneumococcal conjugate vaccine. Can J Infect Dis Med Microbiol 2007, 18(2):121-127.
• [47]International Monetary Fund: World Economic and Financial Surveys, World Economic Outlook Database. [http://www.imf.org/external/pubs/ft/weo/2010/02/weodata/index.aspx webcite]
• [48]Sachs JD: Macroeconomics and Health: Investing in Health for Economic Development. Report of the Commission on Macroeconomics and Health. [http://whqlibdoc.who.int/publications/2001/924154550X.pdf webcite]
• [49]World Health Organization: The World Health report 2002. Reducing risks, promoting healthy life. [http://www.who.int/whr/2002/en/whr02_en.pdf webcite]
• [50]Centers for Disease Control and Prevention (CDC): Direct and indirect effects of routine vaccination of children with 7-valent pneumococcal conjugate vaccine on incidence of invasive pneumococcal disease - United States, 1998–2003. MMWR Morb Mortal Wkly Rep 2005, 54(36):893-897.
• [51]Centers for Disease Control and Prevention (CDC): Invasive pneumococcal disease in children 5 years after conjugate vaccine introduction - eight states, 1998–2005. MMWR Morb Mortal Wkly Rep 2008, 57(6):144-148.
• [52]Palmu AA, Jokinen J, Borys D, Nieminen H, Ruokokoski E, Siira L, Puumalainen T, Lommel P, Hezareh M, Moreira M, Schuerman L, Kilpi TM: Effectiveness of the ten-valent pneumococcal Haemophilus influenzae protein D conjugate vaccine (PHiD-CV10) against invasive pneumococcal disease: a cluster randomised trial. Lancet 2013, 381(9862):214-222.
• [53]Mucino-Ortega E, Mould-Quevedo JF, Farkouh R, Strutton D: [Economic evaluation of an infant immunization program in Mexico, based on 13-valent pneumococcal conjugated vaccines]. Value Health 2011, 14(5 Suppl 1):S65-S70.
• [54]Uruena A, Pippo T, Betelu MS, Virgilio F, Giglio N, Gentile A, Jimenez SG, Jauregui B, Clark AD, Diosque M, Vizzotti C: Cost-effectiveness analysis of the 10- and 13-valent pneumococcal conjugate vaccines in Argentina. Vaccine 2011, 29(31):4963-4972.
• [55]Castaneda-Orjuela C, Alvis-Guzman N, Velandia-Gonzalez M, De la Hoz-Restrepo F: Cost-effectiveness of pneumococcal conjugate vaccines of 7, 10, and 13 valences in Colombian children. Vaccine 2012, 30(11):1936-1943.